- Home
- DTIL vs CHPT Comparison
DTIL vs CHPT Comparison
Compare DTIL & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | CHPT |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 125.1M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DTIL | CHPT |
|---|---|---|
| Price | $5.83 | $4.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 10 |
| Target Price | ★ $60.00 | $9.67 |
| AVG Volume (30 Days) | 336.9K | ★ 436.4K |
| Earning Date | 05-14-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,070,000,000.00 | $411,224,000.00 |
| Revenue This Year | N/A | $5.62 |
| Revenue Next Year | $34.75 | $12.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.53 | $0.52 |
| 52 Week High | $8.82 | $12.62 |
Technical Indicators
Market Signals| Indicator | DTIL | CHPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.21 | 35.89 |
| Support Level | $3.96 | $0.61 |
| Resistance Level | $7.59 | $6.73 |
| Average True Range (ATR) | 0.58 | 0.29 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 21.03 | 31.03 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.